- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03449407
Multi-dimensional Investigations of Negative Emotions and Drug-resistant Auditory Verbal Hallucinations in Psychosis
January 22, 2020 updated by: Suzanne Ho-wai So, Chinese University of Hong Kong
Auditory verbal hallucinations (AVH) are commonly reported as source of distress, disability and mortality in schizophrenia.
Despite proven efficacy of antipsychotics, many patients still experience drug-refractory AVH.
It has been postulated that AVH is maintained by negative emotions.
Yet, little is known about the temporal relationship and underlying mechanisms between negative affect and AVH.
Utilizing both an ecologically-validated method and brain imaging technique, this study aims to uncover the role of emotions in the maintenance of psychotic symptoms.
Study Overview
Status
Completed
Study Type
Observational
Enrollment (Actual)
47
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hong Kong, Hong Kong
- Chinese University of Hong Kong
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients, including in-patients, out-patients and day hospital patients, will be recruited from psychiatric units of multiple hospital sites.
Description
Inclusion Criteria:
- Aged 18 to 65 years
- Clinical diagnosis of schizophrenia spectrum disorder
- Present hallucinations
Exclusion Criteria:
- Left-handedness
- Intellectual disability
- Organic psychosis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Psychotic symptomatology as measured by Positive and Negative Syndrome Scale (PANSS), Scale of Assessment for Positive Symptoms (SAPS), and the Psychotic Symptom Rating Scales (PSYRATS)
Time Frame: Baseline
|
Positive and Negative Syndrome Scale (PANSS) is an interview-based assessment of the severity of symptoms associated with schizophrenia, including positive, negative, and general psychopathology.
Scale of Assessment for Positive Symptoms (SAPS) is an interview-based scale of positive symptoms of schizophrenia.
SAPS consists of four areas: hallucinations, delusions, bizarre behaviour and positive formal thought disorder.
Each area includes ratings of specific symptoms and a global rating.
The Psychotic Symptom Rating Scale (PSYRATS) is a 17-item semi-structured interview measuring the severity of multiple dimensions of auditory hallucinations and delusions, including conviction and duration.
|
Baseline
|
Depressive symptomatology as measured by Calgary Depression Scale (CDS)
Time Frame: Baseline
|
Calgary Depression Scale (CDS) is a nine-item structured interview scale that assesses depressive symptoms in patients with schizophrenia.
|
Baseline
|
Beliefs about voices as measured by Beliefs about Voices Questionnaire - Revised (BAVQ-R)
Time Frame: Baseline
|
BAVQ-R is a self-report questionnaire that consists of three subscales pertaining to beliefs about voices: malevolence (i.e.
voices as evil and persecutory), benevolence (i.e.
voices as helpful), and omnipotence (i.e.
voices as controlling and powerful).
|
Baseline
|
Anxiety severity as measured by Beck anxiety inventory (BAI)
Time Frame: 1 week
|
BAI is a self-report questionnaire that measures anxiety severity and unique symptom features that are independent of that in depression, including somatic symptoms and subjective experience of panic and anxiety.
|
1 week
|
Mood states as measured by Visual analogue scale (VAS)
Time Frame: 1 week
|
A simple visual analogue scale assessing state depression, state anxiety and state happiness will be conducted.
|
1 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cognitive capacity as measured by the Wechsler Adult Intelligence Scale - IV (HK) short form (WAIS-IV)
Time Frame: Baseline
|
An instrument developed to assess cognitive ability and the relationship between intellectual functioning and memory of adults.
The WAIS-IV (HK) short form includes four subscales - arithmetic, visual puzzle, information, and coding.
|
Baseline
|
Handedness as measured by Edinburgh Handedness Inventory (EHI)
Time Frame: Baseline
|
A self report questionnaire assessing the dominance of one's right or left hand in everyday activities.
|
Baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 1, 2016
Primary Completion (ACTUAL)
June 30, 2019
Study Completion (ACTUAL)
December 31, 2019
Study Registration Dates
First Submitted
January 23, 2018
First Submitted That Met QC Criteria
February 22, 2018
First Posted (ACTUAL)
February 28, 2018
Study Record Updates
Last Update Posted (ACTUAL)
January 23, 2020
Last Update Submitted That Met QC Criteria
January 22, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Mood&AVH
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia Spectrum and Other Psychotic Disorders
-
VA Office of Research and DevelopmentCompletedSchizophrenia Spectrum & Other Psychotic DisordersUnited States
-
New York State Psychiatric InstituteTemple University; The Zucker Hillside Hospital; Feinstein Institutes for Medical...Not yet recruitingSchizophrenia | Schizoaffective Disorder | Delusional Disorder | Schizophreniform Disorders | Other Specified Schizophrenia Spectrum and Other Psychotic Disorder
-
University of North Carolina, Chapel HillNorth Carolina Department of Health and Human ServicesCompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorders | Unspecified Schizophrenia Spectrum and Other Psychotic DisorderUnited States
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorders | Unspecified Schizophrenia Spectrum and Other Psychotic Disorder | Brief Psychotic DisorderUnited States
-
Laval UniversityCompletedSchizophrenia and Schizophrenia Spectrum PsychosisCanada
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorder | Unspecified Schizophrenia Spectrum and Other Psychotic Disorder | Brief Psychotic DisorderUnited States
-
Columbia UniversityNational Institute of Mental Health (NIMH)RecruitingSchizophrenia | Schizo Affective Disorder | Delusional Disorder | Schizophreniform Disorders | Other Specified Schizophrenia Spectrum and Other Psychotic DisorderUnited States
-
Psychiatric Hospital of the University of BaselActive, not recruitingHarm Reduction | Schizophrenia and Other Psychotic DisordersSwitzerland
-
University of California, San DiegoNational Alliance for Research on Schizophrenia and DepressionCompletedSchizophrenia | Schizoaffective Disorder | Other Primary Psychotic DisordersUnited States
-
Stanford UniversityCompletedPsychotic Disorders | Schizophrenia Spectrum DisordersUnited States